

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey ALCAM/CD166 protein
Trp28-Ala526, with a C-terminal 6-His tag
Accession # XP_005548303

N-terminal Sequence Analysis Trp28

Predicted Molecular Mass 57 kDa

SPECIFICATIONS

SDS-PAGE 67-89 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
When Recombinant Human Cynomolgus Monkey ALCAM/CD166 is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human CD6 Fc Chimera binds with an ED₅₀ of 10-50 ng/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 1 mg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage**
- 12 months from date of receipt, ≤ -20 °C as supplied.
 - 1 month, 2 to 8 °C under sterile conditions after reconstitution.
 - 3 months, ≤ -20 °C under sterile conditions after reconstitution.


DATA

Binding Activity



When Recombinant Cynomolgus Monkey ALCAM (Catalog # 10027-AL) is coated onto a microplate at 1 µg/mL, Biotinylated Recombinant Human CD6 Fc Chimera binds with an ED₅₀ of 10-50 ng/mL.

SDS-PAGE



2 µg/lane of Recombinant Cynomolgus Monkey ALCAM/CD166 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 67-89 kDa.

BACKGROUND

ALCAM (activated leukocyte cell adhesion molecule), designated CD166, is a 100-110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). The cynomolgous ALCAM amino acid (aa) sequence includes a signal peptide, an extracellular domain (ECD) with two V-type and three C2-type Ig-like domains, a transmembrane domain and a short cytoplasmic domain (1). Human ALCAM has several isoforms, including an isoform lacking most of the cytoplasmic domain and a secreted isoform (sALCAM) which antagonizes full-length ALCAM (2, 3). Mature cynomolgous ALCAM ECD shares 93% and 96% aa sequence identity with human and mouse/rat ALCAM, respectively. ALCAM is expressed on multiple cell types including thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte-derived dendritic cells (1, 4). ALCAM mediates low-affinity adhesion with itself or the cysteine-rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1-11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4⁺CD8⁺ T cells (6). Adhesion of ALCAM-expressing antigen presenting cells and CD6-expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (4, 7, 8). High ALCAM expression at the blood-brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on melanoma cell lines appears to be pro-metastatic, but anti-metastatic activity has been reported in breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM-L1, both in the developing retina and invasive melanoma (2, 12).

References:

1. Bowen, M.A. *et al.* (1995) *J. Exp. Med.* **181**:2213.
2. van Kilsdonk, J.W.J. *et al.* (2008) *Cancer Res.* **68**:3671.
3. Ikeda, K. and T. Quertermous (2004) *J. Biol. Chem.* **279**:55315.
4. Zimmerman, A.W. *et al.* (2006) *Blood* **107**:3212.
5. van Kempen, L.C. *et al.* (2001) *J. Biol. Chem.* **276**:25783.
6. Castro, M.A.A. *et al.* (2007) *J. Immunol.* **178**:4351.
7. Nair, P. *et al.* (2010) *Clin. Exp. Immunol.* **162**:116.
8. Masedunskas, A. *et al.* (2006) *FEBS Lett.* **580**:2637.
9. Cayrol, R. *et al.* (2008) *Nat. Immunol.* **9**:137.
10. Degen, W.G. *et al.* (1998) *Am. J. Pathol.* **152**:805.
11. King, J.A. *et al.* (2010) *Mol. Cancer* **9**:266.
12. Buhusi, M. *et al.* (2009) *J. Neurosci.* **29**:15630.